Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).

Trial Details

NCT ID

NCT06728072

Phase

PHASE2

Sponsor

Virginia Commonwealth University

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin

Locations (sample)

Richmond, Virginia, United States|37.55376,-77.46026

Key Eligibility Criteria

Diagnosis of stage IV colorectal cancer
Measurable disease by Response evaluation criteria in solid tumors (RECIST) 1.1 criteria
Planned first-line treatment with a 5FU-based doublet chemotherapy regimen for colon cancer, specifics of the regimen at the discretion of the trea…
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →